Trending...
- VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge
- LaTerra and Respark Under Contract with AIMCO to Acquire a $455M, 7-Property Chicago Multifamily Portfolio
- Record Revenue, Tax Tailwinds, and AI-Driven Scale: Why Off The Hook YS Inc. Is Emerging as a Standout in the $57 Billion U.S. Marine Market
HOPE Therapeutic Subsidiary Focused on Developing a Best-in-Class Network of Clinics for Patients with Suicidal Depression and Related Disorders. HOPE is Planned to be Spun Out as a Separate Company to be Owned by NRXP Shareholders, and New Investors. Effort to be Funded Apart from NRXP.
WILMINGTON, Del. - ncarol.com -- For more information on $NRXP visit: https://www.nrxpharma.com/ OR https://compasslivemedia.com/case-study/nrx-pharmaceuticals/
NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain.
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
More on ncarol.com
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
HIGHLIGHTS
Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD.
Company Funded For New Drug Applications (NDAs) for NRX-100 (ketamine) and NRX-101
Audit of HOPE Therapeutics Subsidiary Complete, SEC Filing of Spinout Planned for Current Quarter.
Secured $10.8 - $16.3 Million Convertible-Debt Funding from an Institutional Investor.
NRX-100 NDA for Suicidal Depression Based on Data from Four Clinical Trials in Nearly 1000 Participants Demonstrating Highly Significant Efficacy.
Ketamine Findings Confirmed in Published 43,000 Person Cohort Study.
More on ncarol.com
Phase 2b/3 Trial Data Presented at the American Society of Clinical Psychopharmacology. Profile Demonstrates Possible Best in Class.
Plans to file New Drug Application for Accelerated Approval under Breakthrough Therapy Designation and Priority Review of NRX-101.
Stability Data Continues to Mature on Three Manufacturing Lots Required for the NRX-100 (IV ketamine) NDA filing.
Company Announced Alignment with FDA on its Pediatric Study Plan for NRX-100, Also a Requirement for Filing of NDA.
Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Country: United States
Website: https://www.nrxpharma.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain.
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
More on ncarol.com
- "BigPirate" Sets Sail: A New Narrative-Driven Social Casino Adventure
- Phinge CEO Ranked #1 Globally by Crunchbase for the Last Week, Will Be in Las Vegas Jan. 4-9, the Week of CES to Discuss Netverse & IPO Coming in 2026
- Fayetteville Concrete Contractors Serves Cumberland County with Concrete Solutions
- Women's Everyday Safety Is Changing - The Blue Luna Shows How
- Microgaming Unveils Red Papaya: A New Studio Delivering Cutting-Edge, Feature-Rich Slots
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
HIGHLIGHTS
Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD.
Company Funded For New Drug Applications (NDAs) for NRX-100 (ketamine) and NRX-101
Audit of HOPE Therapeutics Subsidiary Complete, SEC Filing of Spinout Planned for Current Quarter.
Secured $10.8 - $16.3 Million Convertible-Debt Funding from an Institutional Investor.
NRX-100 NDA for Suicidal Depression Based on Data from Four Clinical Trials in Nearly 1000 Participants Demonstrating Highly Significant Efficacy.
Ketamine Findings Confirmed in Published 43,000 Person Cohort Study.
More on ncarol.com
- 5-Star Duncan Injury Group Expands Personal Injury Representation to Arizona
- NC State and Railinc Partner to Advance Freight Efficiency through Modal Rebalancing Study
- The End of "Influencer" Gambling: Bonusetu Analyzes Finland's Strict New Casino Marketing Laws
- AI-Driven Cybersecurity Leader Gains Industry Recognition, Secures $6M Institutional Investment, Builds Momentum Toward $16M Annual Run-Rate Revenue
- TRIO Heating, Air & Plumbing Now Ranks #1 in San Jose
Phase 2b/3 Trial Data Presented at the American Society of Clinical Psychopharmacology. Profile Demonstrates Possible Best in Class.
Plans to file New Drug Application for Accelerated Approval under Breakthrough Therapy Designation and Priority Review of NRX-101.
Stability Data Continues to Mature on Three Manufacturing Lots Required for the NRX-100 (IV ketamine) NDA filing.
Company Announced Alignment with FDA on its Pediatric Study Plan for NRX-100, Also a Requirement for Filing of NDA.
Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Country: United States
Website: https://www.nrxpharma.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: Corporate Ads
Filed Under: Business
0 Comments
Latest on ncarol.com
- Ability 2 Play Hosts Free Demo Day for Families in Raleigh/Garner Area
- The Nature of Miracles Celebrates 20th Anniversary Third Edition Published by DreamMakers Enterprises LLC
- Artificial Intelligence Leader Releases Children's Book on Veterans Day
- Felicia Allen Hits #1 Posthumously with "Christmas Means Worship"
- CCHR Documentary Probes Growing Evidence Linking Psychiatric Drugs to Violence
- Tokenized Real-World Assets: Iguabit Brings Institutional Investment Opportunities to Brazil
- MEX Finance meluncurkan platform keuangan berbasis riset yang berfokus pada data, logika, dan efisiensi pengambilan keputusan investasi
- From MelaMed Wellness to Calmly Rooted: A New Chapter in Functional Wellness
- New Angles US Group Founder Alexander Harrington Receives Top U.S. Corporate Training Honor and Leads Asia-Pacific Engagements in Taiwan
- UK Financial Ltd Board of Directors Establishes Official News Distribution Framework and Issues Governance Decision on Official Telegram Channels
- UK Financial Ltd Sets Official 30-Day Conversion Deadline for Three Exchange Listed Tokens Ahead of Regulated Upgrade
- New Jersey Therapy and Life Coaching Unveils Original Dan Fenelon Mural in Voorhees New Jersey Therapy Office
- Kentucky Judges Ignore Evidence, Prolong Father's Ordeal in Baseless Case
- Contracting Resources Group Receives 2025 HIRE Vets Platinum Medallion Award from the U.S. Department of Labor
- Peter J. D'Arruda Founder of Capital Financial Joins Tom Hegna on the Podcast "Financial Freedom with Tom Hegna"
- Crunchbase Ranks Phinge Founder & CEO Robert DeMaio #1 Globally. Meet him in Las Vegas-Week of CES to Learn About Netverse, Patented App-less Platform
- Run the Diamond Releases New Winter Workout Album for Baseball and Softball Athletes
- IODefi Introduces New Web3 Infrastructure Framework as XRP Ledger Development Gains Global Attention
- Terizza Forms Strategic Collaboration with UC San Diego to Pioneer Next-Generation Distributed AI Infrastructure
- EnergyStrat Launches Global LNG Risk Outlook 2025–2030